- Home
- PHR vs XERS Comparison
PHR vs XERS Comparison
Compare PHR & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHR
- XERS
- Stock Information
- Founded
- PHR 2005
- XERS 2005
- Country
- PHR United States
- XERS United States
- Employees
- PHR N/A
- XERS N/A
- Industry
- PHR Business Services
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- PHR Consumer Discretionary
- XERS Health Care
- Exchange
- PHR Nasdaq
- XERS Nasdaq
- Market Cap
- PHR 1.4B
- XERS 1.3B
- IPO Year
- PHR 2019
- XERS 2018
- Fundamental
- Price
- PHR $22.64
- XERS $9.70
- Analyst Decision
- PHR Strong Buy
- XERS Strong Buy
- Analyst Count
- PHR 15
- XERS 7
- Target Price
- PHR $33.73
- XERS $9.43
- AVG Volume (30 Days)
- PHR 575.2K
- XERS 2.2M
- Earning Date
- PHR 12-08-2025
- XERS 11-06-2025
- Dividend Yield
- PHR N/A
- XERS N/A
- EPS Growth
- PHR N/A
- XERS N/A
- EPS
- PHR N/A
- XERS N/A
- Revenue
- PHR $449,672,000.00
- XERS $246,025,000.00
- Revenue This Year
- PHR $14.98
- XERS $43.89
- Revenue Next Year
- PHR $12.12
- XERS $20.40
- P/E Ratio
- PHR N/A
- XERS N/A
- Revenue Growth
- PHR 15.31
- XERS 35.62
- 52 Week Low
- PHR $17.07
- XERS $2.82
- 52 Week High
- PHR $32.76
- XERS $10.03
- Technical
- Relative Strength Index (RSI)
- PHR 39.88
- XERS 70.83
- Support Level
- PHR $22.14
- XERS $9.11
- Resistance Level
- PHR $23.87
- XERS $10.03
- Average True Range (ATR)
- PHR 0.78
- XERS 0.42
- MACD
- PHR 0.10
- XERS 0.04
- Stochastic Oscillator
- PHR 37.00
- XERS 84.41
About PHR Phreesia Inc.
Phreesia Inc is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, initial patient contact, registration, automated answering services, appointment scheduling, payments, and post-appointment patient surveys.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).